Clinical trial · Interventional
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC). Zr-89-girentuximab PET/CT (Positron Emission Tomography) may be a valuable imaging technique in the diagnosis of patients with RCC. The aim of the present study is to show the impact of the Zr-89-girentuximab PET/CT on the clinical management of ccRCC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zirconium-89 girentuximab PET/CT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Zirconium-89 girentuximab PET/CT
- description
- A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
- interventionNames
- Drug: Zirconium-89 girentuximab PET/CT
Primary outcomes (1)
- measure
- Impact on clinical decision making
- timeFrame
- 1 year
- description
- Impact on clinical decision making, defined as present or absent: * Absent: e.g. no change in treatment or follow-up * Present: e.g. change in follow-up schedule, change in surgical technique, change from surgery to active surveillance, or change from surgery to systemic treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: In order to participate in this study, a subject must meet all of the following criteria: 1. His or her clinician should face a diagnostic dilemma; e.g. * patients with a renal mass of unknown origin, or * patients with a primary renal mass in whom it is unclear whether there is metastatic disease, or * patients with a history of clear cell RCC with a suspicion of relapse or metastatic disease. 2. Minimum age 18 years 3. Signed informed consent Exclusion Criteria: * History of a CAIX-negative or non clear cell RCC. * Administration of tyrosine kinase inhibiters within 1 month prior to inclusion. * Any medical condition present that in the opinion of the investigator will affect patients' clinical status. - Administration of a radioisotope within 10 physical half lives prior to study enrollment * Pregnancy or lactation. * Known hypersensitivity or HACA (human anti chimeric antibodies) against Girentuximab.
References
Publications (0)
Data not yet available